ARS Pharmaceuticals (SPRY) Shares Outstanding (2020 - 2026)

ARS Pharmaceuticals has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $99.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 1.19% year-over-year to $99.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.3 million (up 1.19% YoY) and the FY2025 annual result came in at $99.3 million, up 1.36% from the prior year.
• Shares Outstanding (Entity) was little changed at $99.3 million in Q1 2026 per SPRY's latest filing, from $99.3 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $99.3 million in Q1 2026 and troughed at $35.1 million in Q1 2022.
• A 5-year average of $83.0 million and a median of $96.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) grew 0.54% in 2022, then soared 170.9% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $40.0 million in 2022, then jumped by 141.3% to $96.4 million in 2023, then advanced by 1.6% to $98.0 million in 2024, then climbed by 1.36% to $99.3 million in 2025, then increased by 0.01% to $99.3 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $99.3 million, $99.3 million, and $98.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.